What is the role of cannabis-based medicine (CBM) in the treatment of spasticity?

Updated: Jun 28, 2019
  • Author: Krupa Pandey, MD; Chief Editor: Stephen A Berman, MD, PhD, MBA  more...
  • Print

Standardized oromucosal whole-plant cannabis-based medicine (CBM): Contains delta-9 tetrahydrocannabinol (THC) and cannabidiol (CBD); may represent a useful agent for the relief of spasticity in multiple sclerosis (MS)

In a double-blind study performed over 6 weeks, in which 189 subjects with MS and spasticity received daily active preparation of standardized oromucosal whole-plant CBM (n=124) or placebo (n=65), the daily subject-recorded Numerical Rating Scale of spasticity showed the active preparation to be significantly superior. Secondary efficacy measures (Ashworth Score and a subjective measure of spasm) also were in favor of active preparation but did not achieve statistical significance. [21]

Another study, a meta-analysis, suggested that combined THC and CBD extracts may provide therapeutic benefit for spasticity in MS patients, although only subjective relief attained statistical significance. [22]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!